Skip to content

Study · Animal study (in vivo) · rat · 2019

4 results

Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot.

Konosic S, Petricevic M, Ivancan V, Konosic L, Goluza E, Krtalic B, Drmic D, Stupnisek M, Seiwerth S, Sikiric P

Oxidative medicine and cellular longevity30 Dec 2019Cited by 45 (Europe PMC)

PMID31976029 (opens in a new tab)PMCIDPMC6955135 (opens in a new tab)DOI10.1155/2019/9084643 (opens in a new tab)PepBankPUB-31976029
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

We suggest that the stable gastric pentadecapeptide BPC 157 may rescue thrombocyte function. We focused on the antithrombotic agent aspirin, clopidogrel, and cilostazol application in rats; arachidonic acid, ADP, collagen, and arachidonic acid/PGE1 platelet aggregation (aggregometry) and blood clot viscoelastic properties (thromboelastometry); and the pentadecapeptide BPC 157. Rats received intragastrically for three days once daily treatment with antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application. For multiple electrode aggregometry and modified rotational thromboelastometry studies, blood sampling was at 2 h after last application. Adenosine diphosphate (ADP test 6.5 μM), arachidonic acid (ASPI test 0.5 mM), a combination of arachidonic acid and prostaglandin E1 (ASPI test 0.5 mM and PGE1-test 30 nM), and collagen (COL test 3.2 μg/ml) were used as aggregation agonists. Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidonic acid/PGE1. Specifically, this includes recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP (vs. clopidogrel), or collagen (vs. clopidogrel). Contrarily, there is no effect on the used tests (extrinsic/intrinsic hemostasis system, the fibrin part of the clot) EXTEM, INTEM, and FIBTEM; clotting time; clot formation time; alpha-angle; maximum clot firmness; lysis index after 30 minutes; and maximum lysis. In conclusion, we revealed that BPC 157 largely rescues thrombocyte function.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given aspirin, BPC‑157 counteracted the inhibition of arachidonic acid-induced platelet aggregation and recovered the aggregation.

    In plain wordsIn rats, BPC‑157 restored blood platelet clumping that aspirin had reduced.

    Peptide
    BPC-157
    Outcome
    IncreaseArachidonic acid-induced platelet aggregation inhibited by aspirin
    Study

    Ratsn: not reported in source

    Aspirin (10 mg/kg) intragastrically for three days; platelet aggregation by multiple electrode aggregometry
    Comparator
    Saline (5 ml/kg) after aspirin
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 μg/kg · Intragastric · Once daily for three days; blood sampling 2 h after the last applicationAs given in this study (Rats).

    Source sentences

    Summary
    Specifically, this includes recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP (vs. clopidogrel), or collagen (vs. clopidogrel).
    2 context sentences
    Summary · context
    Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidonic acid/PGE1.
    Summary · context
    Rats received intragastrically for three days once daily treatment with antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given clopidogrel, BPC‑157 counteracted the inhibition of platelet aggregation induced by arachidonic acid, ADP and collagen and recovered the aggregation.

    In plain wordsIn rats, BPC‑157 restored blood platelet clumping that clopidogrel had reduced.

    Peptide
    BPC-157
    Outcome
    IncreaseArachidonic acid-, ADP- and collagen-induced platelet aggregation inhibited by clopidogrel
    Study

    Ratsn: not reported in source

    Clopidogrel (10 mg/kg) intragastrically for three days; platelet aggregation by multiple electrode aggregometry
    Comparator
    Saline (5 ml/kg) after clopidogrel
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 μg/kg · Intragastric · Once daily for three days; blood sampling 2 h after the last applicationAs given in this study (Rats).

    Source sentences

    Summary
    Specifically, this includes recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP (vs. clopidogrel), or collagen (vs. clopidogrel).
    2 context sentences
    Summary · context
    Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidonic acid/PGE1.
    Summary · context
    Rats received intragastrically for three days once daily treatment with antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given cilostazol, BPC‑157 counteracted the inhibition of platelet aggregation induced by arachidonic acid and by arachidonic acid/PGE1 and recovered the aggregation.

    In plain wordsIn rats, BPC‑157 restored blood platelet clumping that cilostazol had reduced.

    Peptide
    BPC-157
    Outcome
    IncreaseArachidonic acid- and arachidonic acid/PGE1-induced platelet aggregation inhibited by cilostazol
    Study

    Ratsn: not reported in source

    Cilostazol (10 mg/kg) intragastrically for three days; platelet aggregation by multiple electrode aggregometry
    Comparator
    Saline (5 ml/kg) after cilostazol
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 μg/kg · Intragastric · Once daily for three days; blood sampling 2 h after the last applicationAs given in this study (Rats).

    Source sentences

    Summary
    Specifically, this includes recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP (vs. clopidogrel), or collagen (vs. clopidogrel).
    2 context sentences
    Summary · context
    Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidonic acid/PGE1.
    Summary · context
    Rats received intragastrically for three days once daily treatment with antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given aspirin, clopidogrel or cilostazol, BPC‑157 had no effect on thromboelastometry tests (EXTEM, INTEM, FIBTEM, clotting time, clot formation time, alpha-angle, maximum clot firmness, lysis index after 30 minutes, maximum lysis).

    In plain wordsIn rats, BPC‑157 did not change the clot tests measured in blood.

    Peptide
    BPC-157
    Outcome
    No significant changeBlood clot viscoelastic properties (EXTEM, INTEM, FIBTEM; clotting time; clot formation time; alpha-angle; maximum clot firmness; lysis)
    Study

    Ratsn: not reported in source

    Modified rotational thromboelastometry of blood from rats given aspirin, clopidogrel or cilostazol
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 μg/kg · Intragastric · Once daily for three days; blood sampling 2 h after the last applicationAs given in this study (Rats).

    Source sentences

    Summary
    Contrarily, there is no effect on the used tests (extrinsic/intrinsic hemostasis system, the fibrin part of the clot) EXTEM, INTEM, and FIBTEM; clotting time; clot formation time; alpha-angle; maximum clot firmness; lysis index after 30 minutes; and maximum lysis.
    1 context sentence
    Summary · context
    Rats received intragastrically for three days once daily treatment with antithrombotic agents-aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.